tuneTypical Dose
Use product-specific dosing and titrate to bowel response
Supplement
Triphala
Ayurvedic three-fruit blend
Evidence TierCWADA NOT PROHIBITED
watchEffect Window
Bowel effects may appear quickly, while other claims are far less certain.
check_circleCompliance
WADA NOT PROHIBITED
Overview
Clinical Summary
Triphala is best framed as a mild bowel-regularity and digestive-support blend, with much weaker evidence for broad detox or microbiome claims.
Triphala is an Ayurvedic three-fruit formula most commonly used for bowel regularity and digestive support. That is still the most defensible modern framing. Human evidence remains limited and often lower quality, and newer oral-health meta-analytic data are better interpreted as low-certainty niche support than as proof of broad efficacy. Triphala still fits a gentle bowel-support lane much better than detox or microbiome-repair marketing.
Triphala combines three fruits with tannins, polyphenols, and mild laxative activity. The human evidence fits bowel-regularity support better than broad microbiome or detox claims.
Outcomes
What This Is Expected To Influence
Primary Outcomes
- Mild improvement in bowel regularity and constipation symptoms
Secondary Outcomes
- Weak and inconsistent microbiome effects
Safety
Contraindications and Interactions
Contraindications
- Unexplained GI bleeding, severe abdominal pain, or bowel obstruction concern
Side effects
- Loose stools
- Abdominal cramping
Interactions
No entries provided
Avoid if
- You are using it instead of evaluating serious GI symptoms
Evidence
Study-level References
tri-SRC-001Open-label prospective study
Sourceopen_in_newMunshi R, Bhalerao S, Rathi P, et al. An open-label, prospective clinical study to evaluate the efficacy and safety of TLPL/AY/01/2008 in the management of functional constipation. Anc Sci Life. 2011;31(1):5-11. PMID:22022157.
Population: Adults with functional constipation.
Dose protocol: Triphala-containing polyherbal constipation formula for 14 days
Key findings: Improved constipation symptoms over baseline.
Notes: Supportive but low-quality clinical evidence.
Paper content
This study is relevant because it reflects how Triphala is often used clinically, but it is open label and uses a polyherbal formula rather than isolated Triphala. It supports only low-confidence constipation framing.
tri-SRC-002Randomized controlled pilot trial
Sourceopen_in_newPeterson CT, Sharma V, et al. Modulatory Effects of Triphala and Manjistha Dietary Supplementation on Human Gut Microbiota: A Double-Blind, Randomized, Placebo-Controlled Pilot Study. J Med Food. 2021;24(2):121-132. doi:10.1089/jmf.2020.0026. PMID:32955913.
Population: Healthy adults.
Dose protocol: Triphala capsules for 8 weeks
Key findings: Gut microbiota changes were individualized rather than uniform.
Notes: Useful limit-setting study.
Paper content
This pilot trial is useful as a caution against overclaiming Triphala as a proven microbiome modulator. It showed that responses were individualized and there was no uniform microbiota shift. That supports a softer gut-health framing than many supplement labels use.
tri-SRC-003Systematic review and meta-analysis
Sourceopen_in_newMinervini G, Marrapodi MM, Tirupathi S, et al. Comparative anti-plaque and anti-gingivitis efficiency of Triphala versus chlorhexidine mouthwashes in children: a systematic review and meta-analysis. J Clin Pediatr Dent. 2024;48(5):51-59. doi:10.22514/jocpd.2024.103. PMID:39275820.
Population: Children using mouthwashes for plaque and gingivitis control across five clinical trials.
Dose protocol: Triphala mouthwash versus chlorhexidine across five pediatric clinical trials.
Key findings: No significant difference in plaque or gingivitis reduction between Triphala and chlorhexidine mouthwash groups in children.
Notes: Systematic review and meta-analysis. Expands evidence base into oral health, though clinical trials are small.
Paper content
This meta-analysis pooled five small pediatric trials comparing Triphala mouthwash with chlorhexidine for plaque and gingivitis control. The pooled result found no significant difference between groups, which is better interpreted as low-certainty non-inferiority-style evidence than as proof that Triphala is a clinically validated oral-health intervention. It modestly expands the Triphala evidence base beyond bowel-regularity use, but the small underlying studies and pediatric mouthwash context should keep broad claims conservative.
tri-SRC-004Controlled randomized trial.
Sourceopen_in_newSarosh I, Shaukat R, Mustafa A, et al. Determination of chemical composition and investigation of potential of triphala powder in hypercholesterolemia in men in controlled randomized trial. Pak J Pharm Sci. 2023;36(2(Special)):707-711. PMID:37548212.
Population: Hypercholesterolemic men.
Dose protocol: Triphala powder 400-600 mg capsules for 10 weeks.
Key findings: Significant reduction in lipid profile parameters in hypercholesterolemic men.
Notes: Small RCT in a regional journal. Adds a metabolic endpoint but needs replication.
Paper content
This controlled randomized trial tested triphala powder capsules at 400 mg and 600 mg doses in hypercholesterolemic men over 10 weeks. The study found significant reductions in lipid profile parameters in the triphala groups compared to control. While this provides human evidence for triphala's potential hypolipidemic activity, the study is relatively small and published in a regional journal. It adds a metabolic endpoint to the triphala evidence base, which has traditionally focused on bowel regularity and oral health.